Form 4 Tracker
Kory James Wentworth

Chief Financial Officer · 4 filings · Latest: Apr 1, 2026

Entrada Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
TRDA
Kory James WentworthChief Financial OfficerApr 1, 2026
Sale
$12.952,500$32.4K119,010
TRDA
KORY WENTWORTHApr 1, 2026
Proposed Sale
$12.622,500$31.6K
TRDA
Kory James WentworthChief Financial OfficerMar 10, 2026
Sale
$13.0211,388$148.2K121,510
TRDA
Kory James WentworthChief Financial OfficerMar 9, 2026
Sale
$13.005,089$66.2K132,898
TRDA
KORY WENTWORTHMar 9, 2026
Proposed Sale
$12.5816,477$207.3K
TRDA
Kory James WentworthChief Financial OfficerMar 4, 2026
Sale
$12.257,988$97.9K137,987
TRDA
KORY WENTWORTHMar 4, 2026
Proposed Sale
$11.857,988$94.7K
TRDA
KORY WENTWORTHNov 21, 2025
Proposed Sale
$9.178,910$81.7K
TRDA
KORY WENTWORTHMar 17, 2025
Proposed Sale
$10.811,784$19.3K
TRDA
KORY WENTWORTHNov 11, 2024
Proposed Sale
$19.8214,637$290.1K
TRDA
KORY WENTWORTHSep 9, 2024
Proposed Sale
$14.803,195$47.3K